Cannabis Law Report

MAY 18, 2022

NEW STUDY DEMONSTRATES CBD’S STRONG SAFETY PROFILE , AMPLIFIES CALLS FOR FDA REGULATION. Observational Data Collected On Long-term Consumption of Oral C BD Shows No Correlation To Safety Issues Raised by FDA. The second cohort included an additional 222 individuals taking CBD produced by an additional five companies.

Safety 52

Safety Hemp Research and Development Data 52

Cannabis Law Report

DECEMBER 7, 2021

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. Systematic review and meta-analysis were performed to examine the efficacy and safety of MCs treatment among children.

Safety 52

Safety Cannabinoids Events Data 52

Cannabis Law Report

JUNE 23, 2021

Sapphire Medical Clinics presented six abstracts focused on the latest research on cannabinoids based on data from the UK Medical Cannabis Registry during the 31st Annual International Cannabinoid Research Society Symposium on the Cannabinoids (ICRS2021). Patient-reported outcomes. PROGRAMME.and.ABSTRACTS. Improved quality of life.

Cannabinoids 59

Cannabinoids Data Chronic Pain Sleep 59

Cannabis Law Report

APRIL 12, 2019

A patient in Alberta spending $600 (~€397) per month on medical cannabis will pay 24.3% ($145.80) in tax. For most Canadian patients, including myself, this means 24.3% CFAMM’s goal is to support medical cannabis patients, improve their outcomes and enable them to obtain fair and safe access to their medication.

Access 45

Access Patients Marijuana Medicine 45

TheAnswerPage

JANUARY 11, 2022

Are you able to answer your patients’ medical marijuana questions? and ‘The Perioperative Considerations for the Patient Utilizing Cannabinoid-based Medicines and Products.’ million medical marijuana patients nationwide. Written by Dr. Meredith Fisher-Corn, MD , Editor-in-Chief at TheAnswerPage.com.

Patients 98

Patients Education Marijuana Therapy 98

Veriheal

MAY 30, 2023

A new 2023 study published in BMJ Supportive & Palliative Care suggests that cannabis could be the answer millions of cancer patients have been looking for. of patients experience pain after curative treatment, while 66.4% of patients with advanced or metastatic cancer suffer from pain. Interestingly, 72.5%

Medicine 98

Medicine Treatment Patients Data 98

Cannabis Chronicles

MAY 22, 2019

SPOKANE — Researchers at Washington State University are teaming up with the Puyallup Tribe of Indians in an effort to chart the tribe’s outcomes prescribing medicinal marijuana to patients. This partnership with WSU and Qwibil will help us research the safety and efficacy of cannabis as medicine for our patients’ use.”.

Medicine 140

Medicine Research and Development Data Collective 140

MMJ Recs

NOVEMBER 17, 2023

This article explores the profound impact of MMJ on Maryland communities, shedding light on the medical marijuana benefits experienced by patients and the positive effects it has had on the state’s communities. It has the potential to reduce opioid dependence and addiction, leading to safer and healthier communities.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

Cannabis Law Report

SEPTEMBER 1, 2021

This number also underscores the entire agency’s tireless efforts, particularly those of our hardworking staff, to thoughtfully regulate a safe, accessible, and effective adult-use marketplace that keeps critical tenets of our mission – public health, public safety, and equity, among others – front of mind.”.

Marijuana 100

Marijuana Seed-To-Sale Safety Data 100

MMJ Recs

MARCH 16, 2024

Regulations vary significantly by jurisdiction but typically encompass licensing requirements, product safety standards, and distribution protocols. Changes in regulations can have ripple effects throughout the industry, impacting supply chains, investment strategies, and consumer access to medical cannabis products.

Supply Chain 105

Supply Chain Research and Development Marijuana Seed-To-Sale 105

Cannabis Law Report

JUNE 1, 2021

The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. billion, servicing nearly 340,000 active patients.

Clinical Trials 89

Clinical Trials Chronic Pain Data Research and Development 89

Cannabis Law Report

SEPTEMBER 11, 2021

Under the supervision of the Executive Director of the Georgia Access to Medical Cannabis Commission. The position provides daily oversight of complaints of product safety issues, non-compliance, and patient safety issues, qualified personnel registration, as well as application and renewal process for all licenses issued by the Commission.

Compliance 105

Compliance Compliance Seed-To-Sale Data 105

Cannabis Law Report

AUGUST 10, 2021

GW was initially granted marketing authorisation for this medicine in the UK in September 2019 as an adjunctive therapy for seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients two years of age and older. ADDITIONAL INFORMATION.

Pharmaceutical 98

Pharmaceutical Treatment Epilepsy Research and Development 98

Veriheal

NOVEMBER 18, 2022

Texas’ medical cannabis program is in the midst of a massive spike in patient registrations. According to the Texas Department of Public Safety Chief Wayne Muller, the state has averaged a 10% month-over-month increase in medical cannabis patients over the last 18 months. Let us know in the comments!

Edibles 98

Edibles Hemp Epilepsy Programs 98

Cannabis Law Report

JANUARY 31, 2022

This list is available by request to those seeking access to psilocybin through the Special Access Program (SAP), and clinical researchers. These doses are produced under Good Agricultural and Collection Practices and tested for potency and impurities to support patient safety and practitioner confidence.

Research and Development 52

Research and Development Clinical Trials Packaging Access 52

SpeedWeed

MARCH 6, 2021

Public safety at issue. Proponents of these THC caps—who are often the same politicians who stood against legalization and lost—contend that limiting THC levels will increase public safety. Forcing patients to purchase more. Doing so, Pollara wrote, would effectively force a 50% to 150% tax on patients.

THC 52

THC Patients Law Chronic Pain 52

Cannabis Law Report

JULY 22, 2022

As the only track-and-trace company to have successfully taken over a government contract from another vendor, Metrc will replace the State’s current partner and implement its robust track-and-trace platform to help facilitate the Rhode Island Medical Cannabis Program’s data collection and regulatory oversight. and now Rhode Island.

Data 52

Data Programs Access Compliance 52

Cannabis Law Report

JUNE 16, 2021

Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. This engagement will build on the strong foundation on Santé, having treated more than 10,000 patients since 2014 under a real-world data protocol.

Clinical Trials 104

Clinical Trials Therapy Research and Development Events 104

Cannabis Law Report

AUGUST 16, 2022

Seamless data tracking helps operators optimize inventory control, accurately report sales data, and improve cultivation management. We are eager to work side-by-side with the Metrc team to establish a well-regulated supply chain to ensure the long-term safety and security of patients and providers.”.

Seed-To-Sale 52

Seed-To-Sale Supply Chain Data Patients 52

Cannabis Law Report

APRIL 5, 2022

Metrc will help facilitate Mississippi’s medical cannabis program’s data collection and regulatory oversight through its robust track-and-trace platform. State regulators can also conveniently access this same information, which will be essential in creating a safe and secure marketplace for both patients and providers. “We

Safety 52

Safety Patients Dispensary Compliance 52

Cannabis Law Report

JUNE 15, 2021

Under the supervision of the Executive Director of the Georgia Access to Medical Cannabis Commission. The position provides daily oversight of complaints of product safety issues, non-compliance, and patient safety issues, qualified personnel registration, as well as application and renewal process for all licenses issued by the Commission.

Compliance 105

Compliance Compliance Seed-To-Sale Data 105

MMJ Recs

FEBRUARY 23, 2024

The foundational framework was laid with the establishment of the Michigan Medical Marijuana Program in 2008, signalling the state’s commitment to providing legal access to cannabis for qualified patients. Patients benefit from a broad spectrum of cannabis products addressing various medical conditions.

Marijuana 52

Marijuana Dispensary Supply Chain Research and Development 52

Veriheal

APRIL 11, 2022

You don’t take that opium poppy and ask a patient to rub it on their lip for morphine. We know that the plant has powerful potential medical effects, but it clearly needs more refinement, more research and more data,” stated Groff, who envisions a future where patients can easily access ailment-targeted cannabis meds.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

The Cannigma

JULY 1, 2022

Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. These claims influence things like how consumers purchase cannabis or how doctors consult with medical cannabis patients.

Research and Development 108

Research and Development Data THC Clinical Trials 108

Veriheal

AUGUST 3, 2021

Under the terms of the legislation, House Bill 1024 will extend cannabis curbside services and indefinitely eradicate the patient cap for actively serving caregivers. In addition to this, patients will be given the opportunity to acquire a 90-day supply of cannabis. Previously, registered patients were limited to a 30-day supply.

Legislation 98

Legislation Patients Supply Chain Dispensary 98

Cannabis Law Report

SEPTEMBER 29, 2022

The Act came into force on October 17, 2018, with two key objectives: To protect the health and safety of Canadians. Prior to the Act’s implementation in 2018, that number sat at 9% according to Health Canada data. Progress towards providing adults with access to strictly regulated, lower-risk, legal cannabis products.

Legislation 59

Legislation Consumption Safety Access 59

SpeedWeed

JULY 25, 2021

At long last the Georgia Access to Medical Marijuana Commission chose six companies that will be allowed to grow, manufacture and sell medical marijuana oil capped at 5% THC. Ed Keating is a co-founder of Cannabiz Media and oversees the company’s data research and government relations efforts. Your submission has been received!

Media 52

Media Data Dispensary Access 52

Cannabis Law Report

APRIL 1, 2022

The highest representative of Spanish pharmacists has proposed carrying out a pilot test in pharmacies to assess the use of cannabis for therapeutic purposes that will serve to collect data on the efficacy and safety of the use of cannabis-derived products. Cannabis and the risk of mental illness. Source: [link].

Medicine 52

Medicine Data Safety Conditions 52

Cannabis Law Report

SEPTEMBER 18, 2021

Under the supervision of the Executive Director of the Georgia Access to Medical Cannabis Commission. The position provides daily oversight of complaints of product safety issues, non-compliance, and patient safety issues, qualified personnel registration, as well as application and renewal process for all licenses issued by the Commission.

Compliance 52

Compliance Compliance Seed-To-Sale Data 52

Cannabis Law Report

AUGUST 18, 2019

There are concerns that government ‘haste’ to widen patient access to cannabis-based medicines by year’s end will expose doctors to legal threat, leaving them caught in the crossfire between patient demand and their professional obligations. Here’s the introduction to the piece at Scoop.

Medicine 45

Medicine Patients Data Safety 45

Cannabis Law Report

SEPTEMBER 29, 2021

With more states legalizing cannabis for medical and recreational use, TCI recognizes the critical role that education plays in reducing patient adverse outcomes and ensuring the safe use of cannabis. In addition, Dr. Roberts sees patients at her private practice in Manhattan. TCI was founded by Drs.

Cannabinoids 52

Cannabinoids Education Patients Safety 52

Cannabis Law Report

JULY 30, 2019

Cannabis-based products will be allowed to bypass usual processes required for medicines in New Zealand and go directly onto the market without any proof of safety or effectiveness. This unprecedented proposal is contained in the government’s consultation document on giving greater access to medicinal cannabis.

Medicine 40

Medicine Clinical Trials Safety Access 40

Cannabis Law Report

AUGUST 12, 2021

This regulative environment also promotes economic growth and significant medical benefits, boosting consumer safety and accessibility. Introducing cross-border electronic prescriptions could enhance patient safety and increase tracking, as the system would be used domestically and internationally.

Legalization 59

Legalization Pharmaceutical Safety Extraction 59

Cannabis Law Report

SEPTEMBER 20, 2021

provides Heritage and subsidiary Opticann the benefits of offering patients access to safe, convenient, and effective CB4 products developed on trusted technology platforms. The products leverage pharmaceutical technology to maximize performance and safety. TORONTO–(BUSINESS WIRE)–Heritage Cannabis Holdings Corp.

Clinical Trials 52

Clinical Trials Pharmaceutical Data Patients 52

Cannabis Law Report

AUGUST 27, 2021

The Board will advise Delic and its subsidiaries, including Ketamine Infusion Centers, Delic Labs and others, as they develop safety protocols and best practices pertaining to legal psychedelic wellness treatments today and those legalized in the future. About Delic Corp, Inc.

Research and Development 98

Research and Development Treatment Media Medicine 98

Cannabis Law Report

AUGUST 17, 2021

reduction in 28-day seizure frequency relative to baseline in tuberous sclerosis complex (TSC) patients (n=23). reduction was observed in focal seizures (n=19), the most common seizure type in TSC patients. Phase 3 planning for TrustTSC trial ongoing with first patient expected to be enrolled in Q4 2021. Data Highlights.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. COMP360 psilocybin therapy has now been given to 233 patients, exceeding 216 target. On track to report top-line data by end of 2021. million, or $0.79 million, or $2.61

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98